Business
Corbus Pharmaceuticals Appoints Rachelle Jacques to Board of Directors
Appointment brings global commercialization and marketing experience for rare diseasesto the Board of DirectorsAppointment aligns with Company's vision to
About this update from Corbus Pharmaceuticals Holdings, Inc.
[{"type":"text","content":"Appointment brings global commercialization and marketing experience for rare diseasesto the Board of DirectorsAppointment aligns with Company's vision to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemNorwood, MA, April 08, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) (\"Corbus\" or the \"Company\") today announced the appointment of Rachelle Jacques to its Board of Directors.Ms. Jacques has more than two decades of experience in U.S. and global commercial leadership and marketing, including launching multiple medicines for rare diseases. She currently serves as Chief Executive Officer of Enzyvant Therapeutics, Inc, a private biopharmaceutical company focused on developing therapies for patients with rare diseases. Prior to joining Enzyvant, Ms. Jacques was the Senior Vice President and Global Complement Franchise Head at Alexion Pharmaceuticals, Inc., responsible for global commercialization strategy and execution of therapies for rare diseases. Previously, she was Vice President of U.S Hematology Marketing at Shire plc, which acquired Baxalta Inc. She also served as Vice President of Business Operations at Baxalta after its spinoff from Baxter International Inc.\"We are delighted to welcome Rachelle to our Board of Directors,\" said Alan Holmer, Chairman of Corbus' Board of Directors. \"She brings invaluable biopharmaceutical industry perspective to Corbus gained from her over 25-year career. We look forward to benefiting from her exceptional insights into business operations as well as global and country-specific commercial marketing and sales as the Company lays the groundwork for its commercialization strategy.\"\"I have come to recognize and admire the pioneering work Corbus is undertaking in the development of treatments for rare inflammatory and fibrotic diseases, and I am excited to join a team that shares my dedication to patient-centric health solutions,\" stated Ms. Jacques. \"I look forward to working with Corbus' leadership team and my fellow directors as the Company develops its go-to-market commercial strategies ahead of topline results from several key studies in 2020.\"\"Rachelle is an accomplished biopharmaceutical executive with extensive commercial experience building and scaling successful drug franchises, and ...